Madrigal Pharmaceuticals, Inc. (MDGL) Stock

Madrigal Pharmaceuticals, Inc. is a forward-thinking clinical-stage biopharmaceutical company dedicated to advancing therapeutic candidates aimed at addressing cardiovascular, metabolic, and liver diseases. Central to its innovative pipeline is resmetirom, the company's lead product candidate. This liver-directed selective thyroid hormone receptor-� agonist is currently undergoing Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), a significant unmet medical need affecting millions globally.

In addition to resmetirom, Madrigal Pharmaceuticals is advancing MGL-3745, a backup compound designed to complement its primary therapeutic efforts. This diversified approach underscores the company's commitment to developing novel treatments that can potentially transform patient care in the fields of liver and metabolic health.

With a strategic focus on research and development, Madrigal Pharmaceuticals has established a collaborative partnership with Hoffmann-La Roche, enhancing its capabilities in advancing innovative therapies from discovery through to commercialization. This partnership exemplifies the company's proactive approach to leveraging scientific expertise and resources to accelerate the development of promising new treatments.

Headquartered in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals continues to expand its footprint in the biopharmaceutical industry. Founded on a dedication to scientific rigor and patient-centered innovation, the company remains poised to make significant strides in addressing complex diseases and improving outcomes for patients worldwide.